| Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer. | Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer.
Tao D, Guan B, Li Z, Jiao M, Zhou C, Li H. | 08/17/2023 |
| Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens. | Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens.
Dai J, Zheng H, Jin J, Cheng Y, Xu H. | 06/5/2023 |
| Claudin-18. | Claudin-18.
Wong MT, Singhi AD, Larson BK, Huynh CAT, Balzer BL, Burch M, Dhall D, Gangi A, Gong J, Guindi M, Hendifar AE, Kim SA, de Peralta-Venturina M, Waters KM. | 06/20/2023 |
| FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer. | FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
Liu Y, Sun Y, Wang P, Li S, Dong Y, Zhou M, Shi B, Jiang H, Sun R, Li Z., Free PMC Article | 04/15/2023 |
| Strong Annexin A10 Expression Supports a Pancreatic Primary and Combined Annexin A10, Claudin 18, and SOX2 Expression Supports an Esophagogastric Origin in Carcinomas of Unknown Primary. | Strong Annexin A10 Expression Supports a Pancreatic Primary and Combined Annexin A10, Claudin 18, and SOX2 Expression Supports an Esophagogastric Origin in Carcinomas of Unknown Primary.
Isidro RA, Abukhiran I, Dunseth CD, Gosse MD, Humble RM, Pelletier DJ, Varshney N, Bellizzi AM, Hornick JL. | 03/20/2023 |
| Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours. | Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours.
Wang F, Yang Y, Du X, Zhu X, Hu Y, Lu C, Sui L, Zhao H, Song K, Yao Q., Free PMC Article | 01/21/2023 |
| Claudin-18 expression in small bowel adenocarcinoma: a clinico-pathologic study. | Claudin-18 expression in small bowel adenocarcinoma: a clinico-pathologic study.
Arpa G, Fassan M, Guerini C, Quaquarini E, Grillo F, Angerilli V, Guzzardo V, Lonardi S, Bergamo F, Lenti MV, Pedrazzoli P, Paulli M, Di Sabatino A, Vanoli A., Free PMC Article | 01/11/2023 |
| RhoA, Claudin 18, and c-MET in Gastric Cancer: Clinicopathological Characteristics and Prognostic Significance in Curative Resected Patients. | RhoA, Claudin 18, and c-MET in Gastric Cancer: Clinicopathological Characteristics and Prognostic Significance in Curative Resected Patients.
Pereira MA, Ramos MFKP, Dias AR, Cardili L, Ribeiro RRE, de Castria TB, Zilberstein B, Nahas SC, Ribeiro U Jr, de Mello ES., Free PMC Article | 07/30/2022 |
| Claudin-18 as a Promising Surrogate Marker for Endocervical Gastric-type Carcinoma. | Claudin-18 as a Promising Surrogate Marker for Endocervical Gastric-type Carcinoma.
Kiyokawa T, Hoang L, Pesci A, Alvarado-Cabrero I, Oliva E, Park KJ, Soslow RA, Stolnicu S., Free PMC Article | 04/30/2022 |
| Gastric Cancer CAR T-cell Target Antigen ID'd. | Gastric Cancer CAR T-cell Target Antigen ID'd.
| 04/16/2022 |
| Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy. | Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
Iwaya M, Hayashi H, Nakajima T, Matsuda K, Kinugawa Y, Tobe Y, Tateishi Y, Iwaya Y, Uehara T, Ota H. | 02/12/2022 |
| [A review on the effect of Claudin-18 on bronchopulmonary dysplasia in preterm infants]. | [A review on the effect of Claudin-18 on bronchopulmonary dysplasia in preterm infants].
Zuo JY, Tong YJ, Yue DM., Free PMC Article | 07/10/2021 |
| Analysis of the expression and genetic alteration of CLDN18 in gastric cancer. | Analysis of the expression and genetic alteration of CLDN18 in gastric cancer.
Li J, Zhang Y, Hu D, Gong T, Xu R, Gao J., Free PMC Article | 03/27/2021 |
| Claudin-18 as a Marker for Identifying the Stomach and Pancreatobiliary Tract as the Primary Sites of Metastatic Adenocarcinoma. | Claudin-18 as a Marker for Identifying the Stomach and Pancreatobiliary Tract as the Primary Sites of Metastatic Adenocarcinoma.
Li WT, Jeng YM, Yang CY. | 01/16/2021 |
| immunophenotyping with CLDN18, CDH17, and PAX8 might improve the diagnostic accuracy of histopathological classifications of endocervical adenocarcinoma | Immunophenotype analysis using CLDN18, CDH17, and PAX8 for the subcategorization of endocervical adenocarcinomas in situ: gastric-type, intestinal-type, gastrointestinal-type, and Müllerian-type.
Asaka S, Nakajima T, Kugo K, Kashiwagi R, Yazaki N, Miyamoto T, Uehara T, Ota H. | 04/25/2020 |
| present study showed that intestinal-type adenocarcinoma with anastomosing glands represents a genetically distinct group of tumors with the frequent presence of RHOA mutations and CLDN18-ARHGAP fusions | RHOA mutations and CLDN18-ARHGAP fusions in intestinal-type adenocarcinoma with anastomosing glands of the stomach.
Hashimoto T, Ogawa R, Tang TY, Yoshida H, Taniguchi H, Katai H, Oda I, Sekine S. | 12/21/2019 |
| Higher expression of CLDN18.2 was observed in diffuse-type and HER2-positive gastric cancers. Meanwhile, CLDN18.2 expression was not associated with survival in patients with gastric cancer. | Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
Baek JH, Park DJ, Kim GY, Cheon J, Kang BW, Cha HJ, Kim JG. | 12/14/2019 |
| Results suggested that a reduction in CLDN18-dependent ZO-2 expression enhances MMP2 expression in lung adenocarcinoma cells, resulting in the promotion of the cell migration. | ZO-2 Suppresses Cell Migration Mediated by a Reduction in Matrix Metalloproteinase 2 in Claudin-18-Expressing Lung Adenocarcinoma A549 Cells.
Akizuki R, Eguchi H, Endo S, Matsunaga T, Ikari A. | 07/13/2019 |
| CLDN18 is a new metaplasia marker in gallbladder tissues, and is conserved in approximately half of gallbladder cancer cases | Mucin 5B, carbonic anhydrase 9 and claudin 18 are potential theranostic markers of gallbladder carcinoma.
Espinoza JA, Riquelme I, Sagredo EA, Rosa L, García P, Bizama C, Apud-Bell M, Leal P, Weber H, Benavente F, Vargas S, Romero D, Kalergis AM, Roa JC. | 06/15/2019 |
| These observations indicate that a fusion gene between CLDN18 and ARHGAP is enriched in younger age-onset gastric cancers, and its presence could contribute to their aggressive characteristics. | Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults.
Nakayama I, Shinozaki E, Sakata S, Yamamoto N, Fujisaki J, Muramatsu Y, Hirota T, Takeuchi K, Takahashi S, Yamaguchi K, Noda T., Free PMC Article | 04/20/2019 |
| data indicate a tumor suppressor role for CLDN18.1 in LuAd mediated by a regulatory network that encompasses YAP/TAZ, IGF-1R and AKT signaling | CLDN18.1 attenuates malignancy and related signaling pathways of lung adenocarcinoma in vivo and in vitro.
Luo J, Chimge NO, Zhou B, Flodby P, Castaldi A, Firth AL, Liu Y, Wang H, Yang C, Marconett CN, Crandall ED, Offringa IA, Frenkel B, Borok Z., Free PMC Article | 03/16/2019 |
| In this study, we found downregulation of miR-767-3p and upregulation of CLDN18 in lung adenocarcinoma tissue and cell lines. | miR-767-3p Inhibits Growth and Migration of Lung Adenocarcinoma Cells by Regulating CLDN18.
Wan YL, Dai HJ, Liu W, Ma HT., Free PMC Article | 12/29/2018 |
| CDH17 and CLDN18 are useful target molecules. Their coupling can aid in the comprehensive detection and localization of gastric cancer metastases in vivo to overcome challenges associated with intratumoral heterogeneity. | Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.
Matsusaka K, Ushiku T, Urabe M, Fukuyo M, Abe H, Ishikawa S, Seto Y, Aburatani H, Hamakubo T, Kaneda A, Fukayama M., Free PMC Article | 02/10/2018 |
| Bile duct adenocarcinoma cells overexpress claudin-18 via the EGFR/RAS/ERK pathway, contributing to cell proliferation and invasion. | Claudin-18 coupled with EGFR/ERK signaling contributes to the malignant potentials of bile duct cancer.
Takasawa K, Takasawa A, Osanai M, Aoyama T, Ono Y, Kono T, Hirohashi Y, Murata M, Sawada N. | 09/30/2017 |
| The presented data substantiate the hypothesis that claudin-18 is a central barrier-forming component of tight junctions and show that IL-13 downregulates claudin-18. These data also suggest that the loss of claudin-18 is associated with increased sensitization to aeroantigens and airway responsiveness | Claudin-18 deficiency is associated with airway epithelial barrier dysfunction and asthma.
Sweerus K, Lachowicz-Scroggins M, Gordon E, LaFemina M, Huang X, Parikh M, Kanegai C, Fahy JV, Frank JA., Free PMC Article | 07/22/2017 |